Shares of Halozyme have been sliced in half after hours, wiping out more than $450 million in value. This is what happens when a binary event goes bad. The following video has all the gory details and discusses what's next for Halozyme. Fool on!
Many investors are attracted to Halozyme and biotechs like it, since they hold the allure of substantial short-term gains. But there's more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as discuss some winning wealth-building strategies. Click here to start reading.
Dave Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
This News Explains Halozyme Therapeutics' Double-Digit Drop Today
Shares fall after an analyst lowers his price target. Here's what investors need to know.
3 Top Stocks Wall Street Is Overlooking
Just because investors are ignoring these three gems doesn't mean that you have to.
Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High
Investors cheer better-than-expected earnings and a guidance boost. Could there be more upside ahead?